Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

PX128

- PMLiVE

Johnson & Johnson’s Yuvanci granted EC approval to treat pulmonary arterial hypertension

Yuvanci is now the only single tablet combination therapy for PAH patients in Europe

- PMLiVE

British Skin Foundation receives £10,000 donation from Circle Health Group

The healthcare provider’s previous donation is supporting research into early melanoma detection

- PMLiVE

UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa

The inflammatory skin disease affects about 1% of the population in most studied countries

- PMLiVE

Quality in Care (QiC) Dermatology 2025

The Awards recognise initiatives that improve the quality of life for people living with skin conditions

- PMLiVE

LEO Pharma’s Anzupgo cream approved by EC to treat chronic hand eczema

About 70% of patients with severe cases of the skin condition report problems performing everyday activities

- PMLiVE

Eli Lilly/Almirall share positive long-term results for Ebglyss in atopic dermatitis

The inflammatory skin condition occurs in approximately 7.3% of adults in the US

- PMLiVE

J&J’s Rybrevant combination approved by FDA to treat EGFR-mutated NSCLC

Alterations in EGFR are among the most common driver mutations in lung cancer patients

- PMLiVE

J&J’s Rybrevant combination shows positive overall survival trend in late-stage lung cancer study

Alterations in EGFR are among the most common driver mutations in NSCLC patients

- PMLiVE

Medscape Education and Comprehensive Medical Mentoring Program Partner to Empower the Next Generation in Dermatology

In a significant stride toward fostering diversity and inclusivity in dermatology, Medscape Education and the Comprehensive Medical Mentoring Program (CMMP) have established a unique alliance to address critical gaps in...

Medscape Education

- PMLiVE

Eli Lilly announces FDA approval for Ebglyss in moderate-to-severe atopic dermatitis

The inflammatory skin condition occurs in 7.3% of adults in the US

- PMLiVE

Johnson & Johnson’s IL-23 inhibitor Tremfya granted FDA approval for ulcerative colitis

The inflammatory bowel disease is estimated to affect more than one million people in the US

- PMLiVE

J&J presents positive late-stage results for Rybrevant/Lazcluze combination in NSCLC

The chemotherapy-free regimen was approved in the US last month for advanced lung cancer patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links